The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer
7 Aug 2018
The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer
Key advances in ALL and AML
Four studies about relapsed myeloma and advanced disease
The role of observational epidemiology in cancer research
The ICMC: a new path for microbiome research
Staffing shortages and need for education support reported in UK gynaecological clinician survey
Surgical management of borderline ovarian tumours
Conference highlights and upcoming events
Extended genetic testing and GYN cancer risk
Surgical highlights from BGCS
Discrepancy of care for ovarian and vulval cancer across the UK
“The Danish Model” - Improving cancer survival in Denmark